Clinical safety and efficacy of red blood cell components treated with the second generation s-303 pathogen and leukocyte inactivation system – a randomized controlled double-blind phase 3 study in patients requiring transfusion support of acute anemia

German Red Cross Blood Donor Service Baden-Wuerttemberg-Hessen, Frankfurt, Germany; Department of Thoracic and Cardiovascular Surgery, Johann Wolfgang Goethe University, Frankfurt, Germany; Department of Haemostaseology and Transfusion Medicine, Kerckhoff-Klinik, Bad Nauheim, Germany; University Clinic Munich, Department for Transfusion Medicine, Cell Therapy and Hemostaseology, Munich, Germany Cerus Corporation, Concord, United States

Transfusion Medicine and Hemotherapy. 2015;42((Suppl. 1)):4.. Abstract no. FV-02-1.
Study details